Clinical Trial Update: Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update comparing Dara-SVD (daratumumab, selinexor, bortezomib, dexamethasone) with Dara-RVD (daratumumab, lenalidomide, bortezomib, dexam…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Decadron (Dexamethasone)
• Revlimid (lenalidomide)
• Velcade (bortezomib)
• XPOVIO (selinexor)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING